Protagen Secures Nearly $13M in Funding for Diagnostics Work and Protein Biomarker Validation
September 10, 2010
Protagen Secures Nearly $13M in Funding for Diagnostics Work and Protein Biomarker Validation
Using its UNIarray protein array platform, the company plans to focus on the development of serum-based protein biomarker tests for the early detection of multiple sclerosis and the differential diagnosis of prostate cancer.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Protagen to ID Protein Biomarkers in Support of Biogen's MS Drug Development Work
April 1, 2011 / ProteoMonitor - Protagen Collaborates with Bayer Schering on Endometriosis Biomarker Discovery
June 11, 2010 / ProteoMonitor - Protagen Using UNIarray Platform to ID Biomarkers for Use in Lupus Drug Development
August 5, 2011 / ProteoMonitor - Scienion to Supply Protagen with Microarray Batches for Clinical Validation of Protein Biomarkers
April 22, 2011 / ProteoMonitor - Protagen Receives Japanese Patent for UNIclone Technology
August 13, 2010 / ProteoMonitor